1. Home
  2. GIGM vs INDP Comparison

GIGM vs INDP Comparison

Compare GIGM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GIGM

GigaMedia Limited

N/A

Current Price

$1.40

Market Cap

15.3M

Sector

Technology

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$2.14

Market Cap

438.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GIGM
INDP
Founded
1998
2000
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3M
438.4M
IPO Year
2002
2021

Fundamental Metrics

Financial Performance
Metric
GIGM
INDP
Price
$1.40
$2.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.7K
★ 1.4M
Earning Date
10-29-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$0.92
52 Week High
$1.72
$5.96

Technical Indicators

Market Signals
Indicator
GIGM
INDP
Relative Strength Index (RSI) 45.88 45.25
Support Level $1.11 $1.73
Resistance Level $1.52 $3.03
Average True Range (ATR) 0.08 0.59
MACD 0.00 -0.16
Stochastic Oscillator 69.35 2.95

Price Performance

Historical Comparison
GIGM
INDP

About GIGM GigaMedia Limited

GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: